Early research which points us to new cancer therapeutic opportunities
Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar modalities or approaches?
The devil is often in the details, whether it be a different trial design, target or modality, or even in several molecules against the same target where the conformation might offer a subtle yet important variation because it hit the right cell/right compartment.
In our latest post we review three emerging targets and explore how new data may change the way we go about tackling the disease with novel therapeutics.
The examples are all from creative and innovative scientists who set out to better understand the underlying biology in order to improve on what can be done in the clinic.
Begin with the end in mind is often an obvious and yet smart strategy few people do really well…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
